Merck KGaA and sanofi-aventis to Investigate Novel Combinations Against Cancer
- Details
- Category: Merck Group
Merck KGaA has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which its division Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block specific pathways in cancer cells.
Roche provides update on Avastin following reviews in Europe and the United States
- Details
- Category: Roche
- In the European Union, Avastin confirmed as a valuable treatment option in combination with paclitaxel
- In the United States, the company will request a hearing to maintain Avastin as a treatment option for metastatic breast cancer
Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) today announced that it has signed agreements with Zenobia Therapeutics (Zenobia) and Vernalis plc (Vernalis) which will provide Lundbeck with access to know-how relevant for making inhibitors for Leucine-rich repeat kinases.
Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc.
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.
Lundbeck to establish a strong, dedicated sales force behind Lexapro® in China
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) announced a revised agreement with its partner in China, Xian-Janssen Pharmaceuticals Ltd. (Xian-Janssen), that change the terms from the current license agreement for Lexapro® to a co-promotion agreement.
XGEVA(TM) (Denosumab) Significantly Improved Bone Metastasis-Free Survival
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the '147 study, demonstrated that XGEVA significantly improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint),
Genzyme Reiterates Board's Position on sanofi-aventis Tender Offer
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reiterated the unanimous recommendation of its board of directors that shareholders continue to reject the sanofi-aventis $69-per-share tender offer, which has been extended until January 21, 2011.
More Pharma News ...
- Bayer: 35 million Euros for the expansion of the development of biologicals
- Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine
- Middle East and North African leaders seek solutions to diabetes threat
- LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients
- GSK to acquire Nanjing MeiRui Pharmaceuticals in China
- Three Innovative Ideas Receive $10,000 Prizes in Patients | Choices | Empowerment Competition
- Merck KGaA Donation Program Supports Schistosomiasis Control in Africa